Brief: TransCode Therapeutics Acquires Option for Radiotheranostic Technology
19/05/2022 14:41
May 19 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS ACQUIRES OPTION FOR
RADIOTHERANOSTIC
TECHNOLOGY
* TRANSCODE THERAPEUTICS -EXPECTS TO SUBMIT EIND APPLICATION
TO
CONDUCT PHASE 0 FIRST-IN-HUMAN CLINICAL TRIAL WITH RADIOLABELED
TTX-MC138 IN H2 OF 2022
Source text for Eikon: ID:nGNXbCL2BL
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors